Department of Health and Human Services (HHS) Fiscal Year 2022 Agency Report

1. Please provide a summary of your agency’s activities undertaken to carry out the provisions of 

OMB Circular A-119, “Federal Participation in the Development and Use of Voluntary Consensus 

Standards and in Conformity Assessment Activities” and the National Technology Transfer and 

Advance Act (NTTAA). The summary should contain a link to the agency’s standards-specific 

website(s) where information about your agency’s standards and conformity assessment related 

activities are available.

1) Agency for Healthcare Research and Quality (AHRQ)

The mission of AHRQ is to produce evidence to make health care safer, higher quality, more 

accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human 

Services and with other partners to make sure that the evidence is understood and used. AHRQ uses 

voluntary consensus standards in our national Medical Expenditure Panel Survey, in our Healthcare 

Costs and Utilization Project, and in our Quality Indicators. AHRQ supports the U.S. standards 

developing organizations (SDOs) through participation in relevant workgroups. By improving the 

uniformity, accuracy, validity, and digitization of health data used for research and decision making, 

AHRQ increases the robustness of its research findings and the usability of tools developed based on 

these findings.

2) Centers for Disease Control and Prevention (CDC)

Center for Surveillance, Epidemiology, and Laboratory Services(CSELS)

CDC Centers, Divisions, and Programs work in consensus with partners in a voluntary manner to 

develop, evaluate, and apply standards for data capture and dissemination. Below is a summary of 

significant standards for communications, messaging, data structuring and transport. CDC endeavors 

to follow industry or community agreed upon standards with subtle content level modifications to 

accommodate the complex and varied demands of public health whenever possible. During the 

development process, CDC works with local public health departments, academia, non-profits, and 

healthcare industry and information technology partners to collaboratively achieve consensus.

Type / Domain Document Transaction Standard(s) Used Status

• Communications and Directory HL7 CDA ® Release 2 Implementation Guide: Reporting to Public 

Health Cancer Registries from Ambulatory Healthcare Providers, Release 1, DSTU Release 1.1 –

US

• Cancer Reporting:

(Stage 3 MU) HL7 CDA Published

Communications and Directory Implementation Guide for Ambulatory Healthcare Provider 

Reporting to Central Cancer Registries (March 2014)
• Cancer Reporting:

(Stage 2 MU) HL7 CDA Published

Communications and Directory Implementation Guide for Ambulatory Healthcare Provider 

Reporting to Central Cancer Registries (August 2012)

• Cancer Reporting

(Stage 2 MU) HL7 CDA Published

Communications and Directory PHIN Communication and Alerting (PCA) Guide Version 1.3 (April 

27, 2010) Public Health Alerting EDXL V 1.0

CAP V1.1 Published

Communications and Directory PHIN Directory Exchange Implementation Guide Version 1.0 

(May 16, 2007)

Public Health Directory Exchange DSML 1.0 Published

• ELR HL7 Version 2.5.1 Implementation Guide:Electronic Laboratory Reporting to Public Health 

(US Realm), Release 2, HL7 Informative Document (May 2014)

(HL7 account required) Electronic Laboratory Reporting to Public Health HL7 2.5.1 Published

• NNDSS https://wwwn.cdc.gov/nndss/case-notification/message-mapping-guides.html

Specific Notifiable Disease Reporting to Public Health (Final Guides) HL7 2.5.1 Published 

Syndromic Surveillance (HL7 Standard for Trial Use) Syndromic Surveillance Message Mapping 

Guides

Syndromic surveillance transmissions from healthcare providers to public health HL7 Version 

2.5.1,

ICD-10-CM, 

SNOMED-CT, 

LOINC,

Rx Norm, 

UCUM,

CPT4 HL7 Standard for Trial Use v.1. Available on the HL7 website (membership required. 

Syndromic Surveillance PHIN Messaging Guide for Syndromic Surveillance: Emergency 

Department, Urgent Care, Inpatient and Ambulatory Care Settings, Release 2.0 (April 2015)

• Erratum to the PHIN Messaging Guide for Syndromic Surveillance: Emergency Department, 

Urgent Care, Inpatient and Ambulatory Care Settings ADT Messages A01, A03, A04 and A08 

Optional ORU^R01 Message Notation for Laboratory Data HL7 Version 2.5.1 (Version 2.3.1 

Compatible) Release 2.0 April 21, 2015pdf icon

PHIN 2.0 Implementation Guide Meaningful Use Clarifying Document (PDF available on NIST 

Website)external icon

Sending data from emergency department, urgent, ambulatory care and inpatient settings to 

public health authorities

• Certifying 2014 Edition Meaningful Use electronic health record technology HL7 2.5.1 

Published as CDC version 2.0
Center for State, Tribal, Local, and Territorial Support (CSTLTS)

The Centers for Disease Control and Prevention (CDC) Center for State, Tribal, Local, and Territorial 

Support (CSTLTS) has been a key supporter in the development, launch and support of the voluntary 

accreditation program for public health departments. The Public Health Accreditation Board (PHAB), 

a non-profit accrediting body, leads the accreditation program which launched in September 2011. 

Until the establishment of PHAB, there had been no national accreditation program for public health 

departments. The initial national consensus standards were released in July 2011 (Version 1.0), an 

update (Version 1.5) was released in 2014, and PHAB released the Version 2022 Standards and 

Measures in FY22 with support from CDC to produce and vet the new standards. CDC has been 

involved as a partner and funder of this initiative to provide support to PHAB’s accreditation and 

continuous improvement activities as evidenced through its accreditation page at 

(https://www.cdc.gov/publichealthgateway/accreditation/ ). The first cohorts of health

departments were accredited in early 2013. As of the end of FY 2022:

• PHAB has accredited 427 health departments—40 states, six tribes, and 381 local health 

departments (including 314 individually accredited local health departments and 67 county 

health departments through a centralized state application).

• 91% of the U.S. population is served by an accredited health department (HD).

• PHAB began reaccrediting sites in 2018; 81 sites have been reaccredited.

• 497 HDs, including 42 SHDs, are formally in the accreditation process (applied or accredited) and 

are demonstrating how they meet the national standards.

All documents related to the accreditation program (the standards, assessment process guidance, 

glossary, etc.) are available at www.phaboard.org. Annual evaluation findings consistently report 

short- and long-term benefits to participating in accreditation. June 2022 evaluation data indicate 

that the program has stimulated quality improvement (95% of accredited health departments 

agree), improved accountability and transparency (89%), improved the capacity of the department 

to provide high quality programs and services (82%), and improved collaboration across units within 

the health department (88%) one year after accreditation. Four years after accreditation, accredited 

health departments report that the program has helped health departments use health equity as a 

lens for identifying and addressing health priorities (74%) and strengthened the utilization of 

resources (65%). More information about the accreditation program can be found at 

(http://www.phaboard.org) and aggregate accreditation data about health department capacity, 

searchable by PHAB domain, theme, and health department characteristics, can be found at the 

PHAB data portal at (www.phabdata.org).

Division of Cancer Prevention and Control (DCPC)

CDC’s National Program of Cancer Registries (NPCR) works to measure progress in preventing and 

treating cancer, a leading cause of death in the United States. Established by Congress through the 

Cancer Registries Amendment in 1992, NPCR collects data on cancer occurrence (including the type,
extent, and location of the cancer), the type of initial treatment, and outcomes. Today, through 

NPCR, CDC supports central cancer registries in 46 states, the District of Columbia, Puerto Rico, the

U.S. Pacific Island Jurisdictions, and the U.S. Virgin Islands. These data represent 97% of the U.S. 

population.

NPCR follows the data collection and quality standards in the North American Association of Central 

Cancer Registries (NAACCR) consensus documents. Annually, these data are evaluated for quality, 

completeness, and timeliness according to the National Data Quality Standard for 23-month data 

and the Advanced National Data Quality Standard for 12-month data. Data also are evaluated 

according to the USCS Publication Standard before publication. NPCR standards can be found here.

National Center for Health Statistics(NCHS)

The National Center for Health Statistics (NCHS) participates in health data standards activities 

providing public health representation in the development, maintenance, and implementation of 

national healthcare standards. These activities support the divisions within NCHS and have included 

standards and implementation projects within the Division of Vital Statistics (DVS) and the Division 

of Health Care Surveys (DHCS). The Classification and Public Health Data Standards Staff (CPHDSS) 

supports the development of national standards for the center and has worked with NCHS divisions 

in representing their standards development work at national level standards development 

organizations. In support of the agency wide data modernization initiative, divisions mentioned 

below are actively working on standards development efforts to provide a mechanism utilizing 

information obtained from health IT systems for public health reporting.

Division of Vital Statistics (DVS)

The Division of Vital Statistics (DVS) in collaboration with CPHDSS is working with HL7 to 

maintain and create mortality and natality national reporting standards. The mortality standards 

include the continued maintenance and updates of the Vital Records Death Reporting (VRDR) 

FHIR implementation guide (IG). Over the course of 2021 and beyond, the VRDR FHIR IG is being 

updated to include the inter-jurisdictional exchange content that jurisdictions utilize to

exchange data among each other and with NCHS. This work will include substantial changes to 

this specification and these updates will be tested in May 2022. Related to natality reporting

the Birth and Fetal Death (BFDR) FHIR standard was balloted through HL7 in January in 2021 and 

has been published as a standard for trial use. It is also being utilized by two state pilot projects 

who are currently creating a SMART on FHIR application to test data quality in receiving medical 

birth information from an EMR. Listings of the aforementioned published HL7 standards can be 

found here: (http://www.fhir.org/guides/registry/ )Lastly, recent development of a Medicolegal 

Death Investigation (MDI) FHIR standard is underway and will balloted through HL7 in May

2022. This standards development project will aim to support the Medical Examiner and

Coroner (ME/C) community in helping improve the timeliness of these types of data. An

initiative to support these development efforts is known as the National Vital Statistics System 

(NVSS) Community of Practice. The NVSS CoP not only supports the development of national 

standards but also provides resources to jurisdictions on the modernization of their electronic
registration systems. Further information on jurisdictional participation for vital records offices 

can be found here: (https://www.cdc.gov/nchs/nvss/modernization/cop.htm)

Division of Health Care Statistics (DHCS)

The Division of Health Care Statistics in collaboration with CPHDSS is working with HL7 to 

maintain the existing CDA National Health Care Surveys Standards (see: 

http://www.hl7.org/implement/standards/product_brief.cfm?product_id=385). To that end 

NCHS has worked with the HL7 Public Health Working Group to resolve comments on STU 

Releases 1.2 and 3.0 of the National Health Care Surveys CDA Standards and work is in progress 

to ballot two “dot releases” of these standards which are expected to result in the new National 

Health Care Surveys CDA Standards Releases 2.1 and 3.1 in January 2022.

While maintaining its CDA healthcare interoperability standards, DHCS--in collaboration with 

CPHDSS and CDC CSELS colleagues--is developing new HL7 FHIR standards as part of the Making 

EHR Data More Available for Research and Public Health (MedMorph) Project, a PCOR Trust 

Fund funded project. DHCS’s National Health Care Surveys are one of the three core public 

health use cases in the MedMorph Project. In January 2021 MedMorph successfully balloted a 

HL7 MedMorph Reference Architecture (RA) Implementation Guide (IG). This MedMorph RA IG 

establishes a common framework (e.g., FHIR resources, FHIR APIs, FHIR operations, security 

mechanisms) that will be leveraged by multiple public health and research use cases. On 

December 10, 2020, the Health Care Surveys Content Implementation Guide Standard for Trial 

Use (STU) ballot process was started. (http://hl7.org/fhir/us/health-care-surveysreporting/2022Jan/index.html) This Content IG is designed to work “hand in glove” with the 

MedMorph RA IG to allow a low burden way for health care providers to use their EHR’s FHIR 

APIs to submit National Health Care Surveys to NCHS. The content that the Health Care Surveys 

Content IG specifies is highly aligned with the United States Core Data for Interoperability 

(USCDI) which is operationalized in the IG vi HL7 US Core Resource Profiles. It is anticipated that 

the CDA National Health Care Surveys IG Releases will remain in use for the next several years as 

the Health Care Survey FHIR Content IG is piloted in 2022 and then more fully adopted in 2023 

and beyond.

National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP)

Division for Heart Disease and Stroke Prevention (DHDSP)

As much as possible, DHDSP works to follow existing standards in public health activities and 

surveillance. A current project leverages existing CMS eClinical Quality Measures 

(http://hl7.org/fhir/us/cqfmeasures/) to develop use cases for public health surveillance of 

hypertension control (CMS165) and diabetes control (CMS122) from EHR data, using electronic 

case reporting technology (http://build.fhir.org/ig/HL7/case-reporting/) aligned with the FHIR 

reference architecture known as Making EHR Data More Available for Research and Public 

Health (MedMorph). MedMorph refers to a common framework (including FHIR resources, FHIR 

APIs, FHIR operations, and security mechanisms) that can be used in many public health use 

cases.
CDC Diabetes Prevention Recognition Program (DPRP)

The Centers for Disease Control and Prevention established the CDC Diabetes Prevention 

Recognition Program (https://www.cdc.gov/diabetes/prevention/lifestyleprogram/index.html)

as part of the National Diabetes Prevention Program (National DPP) 

(https://www.cdc.gov/diabetes/prevention/index.html). The DPRP is the quality assurance arm 

of the National DPP. It provides information about the location and performance of type 2 

diabetes prevention programs across the US. This includes organizations delivering the National 

DPP lifestyle change program in-person, online, via distance learning, and through a 

combination of these delivery modes. The purpose of the DPRP is to recognize organizations 

that have demonstrated their ability to effectively deliver a proven type 2 diabetes prevention 

lifestyle change program.

The DPRP assures the quality of recognized organizations and provides standardized reporting 

on their performance. The original 2012 DPRP Quality Standards were based on successful 

efficacy and effectiveness studies. In one such efficacy study, the US Diabetes Prevention 

Program research trial (DPP), participants in the lifestyle intervention losing 5-7% of their 

bodyweight experienced a 58% lower incidence of type 2 diabetes than those who did not 

receive the lifestyle intervention (https://www.niddk.nih.gov/about-niddk/researchareas/diabetes/diabetes-preventionprogram-dpp/Documents/DPP_508.pdf). CDC updatesthe 

DPRP Standards every 3 years based on new information available in the scientific literature, 

insights gained through analysis of DPRP data, lessons learned from best practices in the field, 

and public comment.

The DPRP has three key objectives:

• Assure program quality, fidelity to scientific evidence, and broad use of an effective type 2 

diabetes prevention lifestyle change program throughout the United States

• Develop and maintain a registry of organizations that are recognized for their ability to 

deliver the National DPP lifestyle change program to people at high risk

• Provide technical assistance to organizations to assist staff in effective program delivery and 

in problem-solving to achieve and maintain recognition status.

Program delivery organizations must also track results and send data to CDC every 6 months 

based on requirements in the DPRP Standards CDC reviews these data and provides feedback to 

each organization. DPRP evaluation data to date show evaluated participants attended an 

average of 18 core sessions (organizations are required to offer a minimum 22 core sessions) 

and 9 core maintenance sessions (organizations are required to offer a minimum 6 core 

maintenance sessions) in the National DPP lifestyle change program. Participant risk reduction, 

determined using outcomes associated with weight, physical activity minutes, and HbA1c, was 

seen in 52.4% of all evaluated participants. This risk reduction included 48.4% who achieved at
least a 5% weight loss; 34.8% who achieved at least a 4% weight loss combined with at least 150 

min/week on average, of physical activity; and 2% to date who had at least a 0.2% reduction in 

HbA1c (of those who submitted HbA1c information*). As of January 6, 2023, there are 2,140 

CDC-recognized organizations that have collectively enrolled 666,374 participants nationwide 

since the program’s inception.

*Note: The DPRP Standards were revised in 2021, to include HbA1c as a new, optional outcome 

variable. As a result, limited data are currently available on this new variable.

The CDC Diabetes Prevention Recognition Program Standards and Operating Procedures 

describe in detail the DPRP requirements and explain how an organization may apply for, earn, 

and maintain CDC recognition (https://www.cdc.gov/diabetes/prevention/pdf/dprpstandards.pdf) to offer the National DPP lifestyle change program.

National Institute for Occupational Safety and Health (NIOSH)

The National Institute for Occupational Safety and Health (NIOSH) encourages its employees with 

relevant expertise to participate as approved representatives in the development of national and 

international standards activities as part of voluntary consensus standards committees. NIOSH 

currently has 45 staff contributing their expertise to approximately 24 major committee 

organizations (e.g., ANSI, ISO, ASTM, NFPA). Participation by NIOSH staff on such committees affords 

the Institute an opportunity to ensure standards are established using sound evidence-based 

science, as well as to help facilitate the transfer of NIOSH research findings into improved 

occupationally related health and safety practices, procedures, and policies. A list of NIOSHapproved participation in established voluntary consensus standards committees can be found at: 

(http://od.niosh.cdc.gov/Consensus-Standards/Consensus-Standards.html).

The Office of Laboratory Science and Safety (OLSS)

The Office of Laboratory Science and Safety encourages its employees with relevant expertise to 

participate as approved representatives in the development of national and international standards 

activities as part of voluntary consensus standards committees. OLSS currently has 1 staff 

contributing their expertise to the US Technical Advisory Group (TAG) for ISO/TC 212

(https://clsi.org/about/clsi-and-international-standards-development/iso-committees/us-tag-toisotc-212/). This committee is administered by the Clinical Laboratory Standards Institute (CLSI), is 

accredited by the American National Standards Institute (ANSI) and operates in compliance with 

applicable ANSI requirements. Participation by OLSS staff on such committees affords an 

opportunity to ensure standards are established using sound scientific and management expertise, 

as well as to help facilitate awareness of internationally recognized technical laboratory standards in 

OLSS’s mission to promote excellence in scientific research, safety practices, procedures, and 

policies. Specific outputs from the ISO/TC 212 in 2022 included the finalization and publication of a 

new edition of voluntary international standard ISO 15189: 2022

(https://clsi.org/standards/products/iso-documents/documents/iso-15189-2022/ )—Medical 

laboratories—Requirements for quality and competence. This voluntary international standard is 

applicable to medical laboratories developing quality management systems, assessing laboratory 

competence and for confirming or recognizing the competence of medical laboratories by
laboratory users, regulatory authorities, and accreditation bodies. ISO 15189: 2022 is also pertinent 

to point-of-care testing (POCT). In 2022, CDC also announced its new Laboratory Quality Plan

(https://www.cdc.gov/labs/quality-activities.html ).

The Laboratory Quality Plan sets a framework that encourages continuous quality improvement, 

while providing the quality assurance checks that ensure excellent test results. This narrative refers 

to ongoing participation and recent outputs in US Technical Advisory Group (TAG) for ISO/TC 212

(https://clsi.org/about/clsi-and-international-standards-development/iso-committees/us-tag-toisotc-212/ ). This committee is administered by the Clinical Laboratory Standards Institute (CLSI), is 

accredited by the American National Standards Institute (ANSI) and operates in compliance with 

applicable ANSI requirements.

National Center for HIV, Viral Hepatitis, STD, and TB Prevention

The Centers for Disease Control and Prevention (CDC) National Center for HIV, Viral Hepatitis, STD, 

and TB Prevention (NCHHSTP) is a supporter in the development and recommendations to 

standardize pregnancy status reporting. NCHHSTP subject matter experts (SMEs) participated as 

members of the Council of State and Territorial Epidemiologist workgroup on pregnancy status 

reporting, including contributing to recommendations created by this workgroup.

Division of Sexual Transmitted Disease Prevention (DSTDP)

DSTDP is developing a standards-based syphilis and congenital syphilis registry model leveraging 

Fast Healthcare Interoperability Resources (FHIR). FHIR is a standard describing data formats 

and elements and an application programming interface (API) for exchanging electronic health 

records (EHR). To date, FHIR has been used to enhance electronic case reports, specifically 

obtaining data on patient diagnoses, symptoms, medications, and demographics.

Division of Tuberculosis Elimination (DTE)

DTE’s Clinical Research Branch (CRB), through the Tuberculosis Trials Consortium (TBTC), 

conducts programmatically relevant clinical trials to improve treatment options and outcomes 

for tuberculosis disease and latent tuberculosis infection. CRB serves as the sponsor for these 

clinical studies, and, as such, has the regulatory responsibility to submit trial data to the US Food 

and Drug Administration conforming to Clinical Data Interchange Standards Consortium (CDISC) 

standards. Data for all TBTC studies are collected in Clinical Data Acquisition Standards 

Harmonization (CDASH) format and transformed to the Study Data Tabulation Model (SDTM) for 

submission to FDA.

3) Centers for Medicare and Medicaid Services (CMS)

The National Standards Group (NSG) within the Office of Burden Reduction & Health Informatics at 

the Centers for Medicare & Medicaid Services (CMS) is responsible for adopting and enforcing 

national standards and operating rules under the Health Insurance Portability and Accountability Act
of 1996 (HIPAA) Administrative Simplification provisions to increase the electronic exchange of 

health information between covered entities. HIPAA covered entities include health plans, health 

care providers and health care clearinghouses, as defined in HIPAA. Representatives from NSG 

participate with several national standards development organizations as they develop and/or 

update the standards and operating rules in preparation for the next version to be considered for 

adoption. NSG is committed to enforcing adoption of electronic standards by all covered entities, 

including those organizations in the private and public sector, as electronic transaction standards 

will increase efficiency in health care.

The specific transactions (for business operations) developed by these organizations include 

enrollment, eligibility, claims, claim status, electronic funds transfer, remittance advice, prior 

authorization, and attachments. NSG staff participate in workgroups of the standards setting 

organizations listed below:

• Health Level 7 (HL7): (www.HL7.org)

• National Council for Prescription Drug Programs (NCPDP): (www.ncpdp.org)

• American Dental Association: (www.ada.org )

• American Medical Association: (www.ama-assn.org )

• Accredited Standards Organization, Insurance (X12N): (www.x12.org)

• Council for Affordable Quality Healthcare (CAQH) Committee for Operating Rules for 

Information Exchange (CORE) CAQHCORE: (www.caqh.org)

• NACHA (the Electronic Payments Association): (https://www.nacha.org/)

NSG consults with numerous other stakeholder groups, such as the NUCC, NUBC, WEDI, and 

regularly engages with the National Committee on Vital and Health Statistics, advisory body to the 

Secretary.

The Quality Measurement and Value-Based Incentives Group (QMVIG) in the Centers for Clinical 

Standards and Quality (CCSQ) at CMS selects performance measures for use within its various 

quality initiatives including healthcare provider public reporting and value-based purchasing 

programs.

CMS prefers selecting performance measures (https://www.cms.gov/medicare/quality-initiativespatient-assessment-instruments/qualitymeasures?redirect=/qualitymeasures ) that have been 

reviewed through a consensus process, and can be considered consensus-based standards. National 

Quality Forum (NQF), a not-for-profit, nonpartisan, membership-based organization, meets the 

NTTAA definition of a consensus-based organization. CMS currently contracts NQF to execute a 

public and transparent consensus development process to endorse and maintain performance 

measures.

NQF’s consensus development process (CDP) 

(https://www.qualityforum.org/Measuring_Performance/Consensus_Development_Process.aspx ) 
includes an open call for candidate consensus standards (i.e., performance measures); multistakeholder review of scientific and statistical evidence against NQF-endorsement criteria; 

discussion and evaluation of measures by multi-stakeholder experts including patient and caregiver 

advisors; and opportunities for stakeholder feedback and public comments throughout the process. 

The CDP also includes a process for stakeholders and the public to object to measures after they 

receive NQF-endorsement. NQF’s processes are consistent with the NTTAA and OMB Circular A-119.

1) CMS Quality Measures: (https://www.cms.gov/medicare/quality-initiatives-patient-assessmentinstruments/qualitymeasures)

2) National Quality Forum: (http://www.qualityforum.org/) 

4) Food and Drug Administration (FDA)

FDA is responsible for protecting public health by helping to bring safe and effective medical 

products and foods to the U.S. public; and advancing public health by ensuring the public has the 

most accurate, science-based information they need to use medicines and foods to improve and 

maintain their health. Standards help to ensure data and process consistency and enable use of 

advanced technology and analytics in FDA’s performance of its mission.

Where feasible, FDA participates in the development of, and uses voluntary consensus standards to 

help facilitate consistent and predictable product manufacturing and assessment, regulatory testing, 

clinical trial data exchange, and product labeling, just to name a few examples. Information 

exchange with our stakeholders promotes efficiency and awareness in the standards setting 

processes. The Agency looks for the appropriate time, process, and forum by which we can engage 

with standard development organizations. By doing so, FDA can facilitate standard setting activities 

and not hinder or duplicate efforts that are already underway in complementary bilateral or 

multilateral discussions. The use of voluntary consensus standards can increase predictability, 

streamline premarket review, and facilitate market entry for safe and effective products, including 

products of emerging technologies, under FDA regulatory authority.

In addition, FDA participates actively in the standard setting process of the Codex Alimentarius, 

which for over 50 years has provided governments with a venue for adoption of food standards to 

facilitate safety and fair-trade practices. Codex is a joint body of the Food and Agricultural 

Organization of the United Nations and of the World Health Organization, and the standards 

developed through this body are recognized by the World Trade Organization. FDA supports Codex 

through the participation of experts and delegates representing the United States and through 

hosting meetings, along with the (The U.S. Department of Agriculture’s (USDA) USDA Food Safety 

and Inspection Service. While FDA is not obligated to adopt the standards, Codex provides greater 

assurances of the safety of food imports, as many countries that export to the United States will 

adopt Codex standards.
Standards developed through interactions with various standard development bodies, including VCS 

organizations and/ or industry consortia, can provide benefit to both the Agency and our 

stakeholders in multiple ways such as:

• Standards can assist regulatory reviewers with assessment of products and product applications;

• Standards can assist industry with methodologies they can adopt for the assessment of their 

products;

• Standards often result in better utilization of limited internal resources;

• International standards can be used by multiple regulatory regions that can facilitate global 

harmonization, to the extent feasible;

• Direct participation by a broad group of stakeholders in development of standards can result in 

consensus among users, practitioners, manufacturers, and government regulators on safety and 

effective use of regulated products;

• Reduction in the costs and in transcription errors resulting from manual data entry such as for 

registrations and listing and adverse event reporting; and

• Reduction in the cost for incorporating new electronic processes such as electronic food and 

device labeling by leveraging existing exchange standards, business processes and information 

technology (IT) systems.

FDA policy is to help develop and use voluntary consensus standards wherever possible in the 

management of products FDA regulates. FDA supports the letter and spirit of the National 

Technology Transfer and Advancement Act (NTTAA) and the Office of Management and Budget 

(OMB) Directive. For more information about FDA’s policies and procedures related to standards 

management, please see our Staff Manual Guide 9100.1 at: 

(https://www.fda.gov/media/79684/download) 

For more information about FDA data standards and the FDA Data Standards Advisory Board, please 

see: (http://www.fda.gov/ForIndustry/DataStandards/default.htm) 

Center for Devices and Radiological Health (CDRH)

CDRH gained additional authority under the 21st Century Cures Act to enhance its Standards 

Recognition Program. A final guidance titled Recognition and Withdrawal of Voluntary Consensus 

Standards published on September 15, 2020 notes that FDA will publish its rationales about 

recognition decisions, respond to recognition requests within 60 days and establish transition times 

to revised recognized standards (when appropriate). Finally, the guidance reflects FDA’s 

commitment to periodically update the Recognized Standards Database with pending recognitions. 

This means that once FDA conveys its intention to recognize a standard it will appear in the 

standards recognition database. Manufacturers may cite it in premarket submissions and will no 

longer need to wait for the publication of a Federal Register notice.

During FY2022, in accordance with section 514(c), 21 U.S.C. 360d(c), FDA/CDRH published the 

following notices to the Federal Register to announce the addition, withdrawal, correction, and/or
revision of certain consensus standards the Agency will recognize for use towards a declaration of 

conformity in premarket submissions and other requirements for medical devices:

Publications in the Federal Register related to Modifications to the List of Recognized Standards is 

available at 

(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards/ucm123792.htm)

Standardsrecognitions published during FY 2022:

Date Federal Register Notice

December 9, 2021 FR Notice (List #56) [Docket No. FDA-2004-N-0451] 

(https://www.govinfo.gov/content/pkg/FR-2021-12-09/pdf/2021-26635.pdf ) 

April 22, 2022 FR Notice (List #57) [Docket No. FDA-2004-N-0451] 

(https://www.govinfo.gov/content/pkg/FR-2022-04-22/pdf/2022-08571.pdf ) 

August 10, 2022 FR Notice (List #58) [Docket No. FDA-2004-N-0451] 

(https://www.govinfo.gov/content/pkg/FR-2022-08-10/pdf/2022-17150.pdf ) 

Access to the current FDA List of Recognized Consensus Standards, as published and updated in the 

Federal Register, can be found at 

(https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm ) 

Conformity Assessment

In general, conformity assessment activities for FDA-regulated products are conducted under 

applicable regulations and guidance that are informed by our standards development efforts 

described above. Standards may become part of conformance activities as they may provide an 

acceptable approach to ensure compliance with applicable laws and regulations. CDRH’s Standards

and Conformity Assessment Program (S-CAP) (https://www.fda.gov/medical-devices/premarketsubmissions-selecting-and-preparing-correct-submission/standards-and-conformity-assessmentprogram ) has launched a voluntary pilot called the ‘Accreditation Scheme for Conformity 

Assessment,’ or ASCA.

Conceptualized to promote a least burdensome approach to medical device review, ASCA was 

developed in conjunction with the device manufacturing industry, standards development 

organizations and conformity assessment entities. The ASCA Pilot relies upon international 

consensus standards (ISO/IEC 17011 and ISO/IEC 17025) augmented by additional ASCA 

specifications and is designed to increase FDA’s confidence in testing methods and results from

ASCA-accredited testing laboratories. Ultimately the ASCA Pilot is expected to make device review 

more efficient, ensuring patients have access to safe and effective medical devices without 

unnecessary delay. The final guidances outlining program specifications can be found on the ASCA

Pilot web page and listed below:
• ASCA Pilot program guidance: The Accreditation Scheme for Conformity Assessment (ASCA) Pilot 

Program - Final Guidance (https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/accreditation-scheme-conformity-assessment-asca-pilot-programsessment-ascapilot-program )

• Basic Safety and Essential Performance standards-specific guidance: Basic Safety and Essential 

Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory 

Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity 

Assessment (ASCA) Pilot Program (https://www.fda.gov/regulatory-information/search-fdaguidance-documents/basic-safety-and-essential-performance-medical-electrical-equipmentmedical-electrical-systems-and )

• Biocompatibility standards-specific guidance: Biocompatibility Testing of Medical DevicesStandards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) 

Pilot Program (https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/biocompatibility-testing-medical-devices-standards-specific-informationaccreditation-scheme )

The docket number: for these guidances are under docket FDA-2019-D-3805U 

(https://www.regulations.gov/docket/FDA-2019-D-3805 ) published on September 25, 2020.

Under the ASCA Pilot, at the end of FY22, CDRH has provided ASCA recognition to 5 Accreditation 

Bodies and granted ASCA-accreditation to 91 testing laboratories under the scope of standards and 

methods included in the ASCA Pilot, adding 14 testing laboratories in FY 22.

Under the Medical Device User Fee Amendments 2022 (MDUFA V), section 2005 updated ASCA to 

advance from a Pilot to a permanent program as established under Section 514(d) of the Federal 

Food, Drug, and Cosmetic Act (21 U.S.C. 360d(d)). Under MDUFA V, CDRH is committed to improve 

ASCA through continued training of FDA staff and supervisors, testing laboratories and accreditation 

bodies. CDRH will continually report annually on the progress of the ASCA Program and work with 

stakeholders for further input on programmatic improvements and/or considerations for expansion.

Center for Food Safety and Applied Nutrition (CFSAN) and Center for Veterinary Medicine (CVM) 

The FDA Food Safety Modernization Act (FSMA) gives the Agency explicit authority to establish a 

program for accreditation of conformity assessment bodies (identified in the statute as third-party 

auditors) to conduct food safety audits and issue certifications of foreign food facilities for FDAregulated food, which includes human food, pet food, and non-medicated animal feed. In 2015, 

FDA issued regulations (21 CFR Part 1 subpart M) establishing the Accredited Third-Party

Certification Program (https://www.fda.gov/food/importing-food-products-unitedstates/accredited-third-party-certification-program ). The regulations describe the framework, 

procedures, and requirements for accreditation bodies seeking recognition by the FDA, as well as 

requirements for third-party certification bodies seeking accreditation, under the program.

Accreditation bodies and third-party certification bodies may use documentation of their 

conformance with ISO/IEC 17011:2004, ISO/IEC 17021:2011, and ISO/IEC 17065:2012 in meeting the
requirements of the regulations, supplemented as necessary (e.g., to meet the conflict of interest, 

reporting, and notification standards in section 808 of the FD&C Act). FDA recommendations on 

third-party certification body qualifications for accreditation to conduct food safety audits and to 

issue food and/or facility certifications under the voluntary third-party certification program are 

contained in a guidance document entitled, “Third-Party Certification Body Accreditation for Food 

Safety Audits: Model Accreditation Standards: Guidance for Industry and FDA Staff” 

(https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industryand-fda-staff-model-accreditation-standards-third-party-certification-body ) 

As part of these recommendations, FDA cited ISO/IEC 17021:2011 and ISO/IEC 17065:2012, which 

are voluntary consensus standards on accreditation that are widely used in determining the 

qualifications of third-party conformity assessment bodies that audit and certify the food industry. 

As of the end of FY22, the FDA has recognized 4 accreditation bodies which have accredited 13 

certification bodies. FDA maintains an online registry of accreditation bodies recognized, and

certification bodies accredited, under this program (https://www.fda.gov/food/importing-foodproducts-united-states/accredited-third-party-certification-program-public-registry-recognizedaccreditation-bodies ). 

FSMA also gives us express authority to establish a laboratory accreditation program for the 

analyses of human and animal foods. FDA issued a final rule in December 2021 establishing the 

Laboratory Accreditation for Analyses of Foods (LAAF) program (https://www.fda.gov/food/foodsafety-modernization-act-fsma/fsma-final-rule-laboratory-accreditation-analyses-foods-laaf).

The final rule specifies the oversight, uniformity, and standards necessary to help ensure that the 

results of certain food testing of importance to public health are reliable and accurate. Under the 

LAAF program, FDA recognizes accreditation bodies that accredit laboratories to the standards 

established in the final rule (“LAAF accredit”); only LAAF-accredited laboratories may conduct the 

food testing covered by the final rule. The final rule incorporates by reference two voluntary 

consensus standards: ISO/IEC 17011:2017 forms the foundational requirement for accreditation 

bodies, and ISO/IEC 17025:2017 forms the foundational requirement for food testing laboratories. 

Although FDA only recently began implementing the LAAF program, as of the end of FY22 7 

accreditation bodies have been recognized and are in the process of assessing testing laboratories 

that wish to participate. FDA maintains an online registry

(https://datadashboard.fda.gov/ora/fd/laaf.htm) of accreditation bodies recognized under the LAAF 

program; once those accreditation bodies start conferring LAAF-accreditation on laboratories, the 

registry will list them as well.

FDA’s Moffett Proficiency Testing Laboratory (Moffett PT), located within CFSAN’s Office of Food 

Safety, Division of Food Processing Science and Technology and part of the Institute for Food Safety 

and Health (IFSH), has been an ISO/IEC 17043 accredited proficiency testing laboratory since 

February 2017 but has been in operation within FDA in varying capacities since the 1950s. This PT 

program’s scope of work is expansive as it is the official PT provider for FDA’s inter-/intra-agency
programs (CVM Veterinary Laboratory Investigation and Response Network, Office of Regulatory 

Affairs (ORA) Office of Regulatory Science (ORS) Quality Assurance programs/dietary supplement 

adulteration, FDA/USDA Food Emergency Response Network) as well as regulatory and food safety 

programs for milk, shellfish, vitamins, and food microbiology. FDA’s Moffett PT incorporates both 

food microbiological and chemical analytes and matrices based on the historical, current, and 

emerging food safety and defense requirements of the FDA. Microbiological PT schemes, for 

example, include bioterror agents such as B. anthracis (attenuated), Y. pestis (attenuated) or F. 

tularensis (attenuated strains) and food pathogens such as Listeria, Salmonella, Vibrio and others in 

a variety of food products. Chemical PT schemes include glyphosate, tetramine, thallium, aflatoxin 

B1, carbamates, ricin and other toxins in a variety of food products. In addition, FDA’s Moffett PT 

schemes include detection for fraudulent weight loss and erectile dysfunction drugs in dietary 

supplements. Moffett PT’s expansive ISO/IEC 17043 accredited scope of work has greatly 

contributed to the groundwork built by FSMA for model laboratory standards, accreditation, and 

capability building of the nation’s food laboratory networks.

Office of Regulatory Affairs (ORA)

Through self-coordinated or collaborative method development & research to support regulatory 

testing, the ORA Office of Regulatory Science (ORS) laboratory network actively contributes to the 

repertoire of consensus analytical methods that are published in the AOAC’s compendium of the 

Official Methods of Analysis. According to 21CFR2.19, the Official Methods of Analysis of the AOAC 

INTERNATIONAL are specified to be used in cases where a method of analysis is not prescribed in 

the regulation.

Within the framework of a current FDA-USP Cooperative Research and Development Agreement 

(CRADA) (https://www.fda.gov/science-research/cooperative-research-and-developmentagreements-cradas/fda-cradas), ORA/ORS Laboratories also conduct analytical work aimed at 

updating USP pharmaceutical analysis monographs using USP reference materials.

ORA/ORS laboratories are accredited to ISO/IEC 17025:2017 standards. The FDA Forensic Chemistry 

Center (FCC), the ORS forensics specialized lab, is accredited to the standards of ANSI-ASQ National 

Accreditation Board (ANAB) in the field of Forensic Science Testing. ORA/ORS laboratories also 

conform to well established method validation and verification criteria such as ICH, USP, AOAC 

standards when qualifying their analytical methods. Each laboratory in the ORA/ORS network is 

audited by an ISO/IEC 17025:2017 accreditor.

Each laboratory conforms to the core requirements of a Quality Management System (QSM) which 

includes the design and maintenance of a proficiency testing and exercise schedule. This proficiency 

testing program of ORA/ORS laboratories is called the National Check Sample Program and aims to 

provide an assessment of laboratory proficiency in performance of analytical methods in the 

accreditation scope. Some proficiency tests utilized in the National Check Sample Program are 

internally generated sample panels prepared with third party vendor standard materials while other 

proficiency tests are obtained commercially.
ORA/ORS Laboratories are also active members of the Integrated Consortium of Laboratory 

Networks(ICLN) (https://www.icln.org/) and CODEX International (http://www.fao.org/fao-whocodexalimentarius/en/); and adopt consensus standards developed by these organizations that 

pertain to specialized testing areas such as veterinary drug residue testing, radiation testing, and 

pesticide testing.

ORA/ORS in coordination with CFSAN and CVM supports ISO/IEC 17025 accreditation of state food 

testing laboratories through the Manufactured Food Regulatory Program and the Flexible Funding

Model. The program advances the nationally integrated food safety system (IFSS) specifically with 

regards to microbiological and chemical food analyses. This includes preparing state laboratories for 

accreditation enhancements. Data generated by awarded state laboratories will be available to 

inform FDA in its enforcement actions, surveillance, and response to foodborne outbreaks. These 

ISO accredited laboratories aid FDA with additional resources and exceptional data to maintain the 

safety of the food chain.

More detailed information on the Manufactured Food Regulatory Program and other standardsrelated programs managed by ORA can be accessed via the links below:

• Manufactured Food Regulatory Program Standards (https://www.fda.gov/federal-state-localtribal-and-territorial-officials/regulatory-program-standards/manufactured-food-regulatoryprogram-standards-mfrps)

• Flexible Funding Model (https://www.fda.gov/federal-state-local-tribal-and-territorialofficials/grants-and-cooperative-agreements/flexible-funding-model-ffm-infrastructuredevelopment-and-maintenance-state-manufactured-food)

• National Integrated Food Safety System – Laboratory Capacity Building 

(https://www.fda.gov/federal-state-local-tribal-and-territorial-officials/national-integratedfood-safety-system-ifss-programs-and-initiatives/laboratory-capacity-building)

• Voluntary National Retail Food Regulatory Program Standards (https://www.fda.gov/federalstate-local-tribal-and-territorial-officials/grants-and-cooperative-agreements/voluntarynational-retail-food-regulatory-program-standards-vnrfrps-cooperative-agreement-program)

• Animal Feed Regulatory Program Standards (https://www.fda.gov/federal-state-local-tribal-andterritorial-officials/regulatory-program-standards/animal-feed-regulatory-program-standardsafrps-and-preventive-controls-cooperative-agreement-program)

Center for Biologics Evaluation and Research (CBER)

In September of 2021, the Center for Biologics Evaluation and Research’s (CBER) Division of 

Biological Standards and Quality Control (DBSQC), which is in the Office of Compliance and Biologics 

Quality, was audited for ISO 17025:2017: “General requirements for the Competence of Testing and 

Calibration Laboratories” for the biological and chemical testing for product lot release, and ISO 

17034:2016: “General Requirements for the Competence of Reference Material Producers.” These
reference materials included influenza antigens and sheep antisera for influenza vaccine potency 

testing, as well as tetanus and diphtheria antitoxin for flocculation for DTaP vaccines. No deficiencies 

were identified during the audit.

CBER’s Laboratory of Immunobiochemistry (LIB), in the Division of Bacterial, Parasitic and 

Allergenic Products, Office of Vaccines Research and Review, was also audited for ISO 17025: 2017 

in August 2021; no deficiencies were identified. The scope of accreditation for the LIB covers the 

“ELISA Competition Assay for Quantitative Determination of Relative Potency of Allergenic 

Extracts.” Additionally, in October 2020 LIB released E7-Orchard Grass Reference and in August 

2021 released C14-Cat Hair Reference.

CBER coordinates with CDER to implement data standards related to the following:

• Real World Data and Real World Evidence

• Identification of Medicinal Products

• CDISC standardsforstudy data and terminologies (e.g., MedDRA, SNOMED, WHO Drug Global)

• HL7 v3 and FHIR for exchange of data for numerous use cases including labeling, 

drug registration and listing, and other use cases

• HL7 ICSR for adverse event data

• ICH eCTD v 4 for content of regulatory submissions

For more information, see (https://www.fda.gov/industry/study-data-standards-resources/studydata-submission-cder-and-cber) 

The 21st Century Cures Act was signed into law in December 2016. Section 3036 directs the FDA

to collaborate with the National Institute of Standards and Technology (NIST) and FDA 

stakeholders to coordinate and prioritize standards development for regenerative medicine and 

regenerative medicine advanced therapies. CBER awarded a contract to Nexight Group and the 

Standards Coordinating Body (SCB) in 2017 to establish a collaboration consisting of FDA, NIST, 

and stakeholders, to coordinate the development and implementation of the processes and 

criteria to identify and prioritize standards that have a high impact on the quality and safety of 

regenerative medicine products and determine whether the development of any specific standard 

is feasible. This contract has been extended to 2024 with deliverables to include the identification 

of needed standards, the conduct of feasibility assessments for needed standards, maintenance

of the standards web portal that allows for stakeholders to search form standards under 

development and standards available, and stakeholder outreach to experts for input on standards 

under development.
5) Indian Health Service (IHS)

The primary mission of the Indian Health Service (IHS) is to raise the physical, mental, social, and 

spiritual health of American Indians and Alaska Natives to the highest level. Standards and 

conformity assessment activities are an integral part of the effective operations of the IHS in 

achieving its mission. There are health-related standards that are used for numerous purposes in the 

health industry. The IHS has used them for privacy/security, interoperability, 

compliance/accreditation, and certification.

Privacy and security standards are used throughout IHS and comply with Department of Homeland 

Security (DHS) requirements. Privacy and security standards are used for other purposes beyond 

those related to patient and employee data. The IHS also uses privacy and security standards to 

address communication of biomedical diagnostic and therapeutic information for digital imaging, 

telemedicine, national drug codes, energy-efficient and environmentally friendly construction, and 

for reporting medical services and procedures.

Interoperability is achieved within IHS through following standards from various development 

organizations, e.g. the use of Health Level Seven (HL7) schemas and International Classification of 

Disease, Tenth Edition (ICD-10) codes. The HL7 standard allows interoperability among health 

information systems both within and beyond the IHS healthcare environment, such as immunization 

data exchange (including COVID-19) to various state and federal partners. ICD-10 is a clinical 

cataloging system used by IHS and its providers, coders, information technology professionals in 

addition to insurance carriers, government agencies and others use to properly note diseases on 

health records, track epidemiological trends, and assist in medical reimbursement decisions. It 

brings interoperability among disparate systems for information sharing.

Accreditation is a process of review in which healthcare organizations participate to demonstrate

the ability to meet predetermined criteria and standards of accreditation established by a 

professional accrediting agency. DirectTrust Agent accreditation recognizes excellence in health data 

processing and transactions. It ensures compliance with industry-established standards, HIPAA 

regulations and the Direct Project. Accreditation granted by the DirectTrust Agent Accreditation 

Program for Health Information Service Providers from the Electronic Healthcare Network 

Accreditation Commission (EHNAC) and DirectTrust is valid for a two-year period; thereafter, a reaccreditation process take place.

Certification is a process by which an accreditation body assess and verifies the attributes of a 

product in accordance with established requirements or standards. Over the past decade the IHS 

successfully achieved certification of its Electronic Health Record for both ambulatory and inpatient 

settings against the 2011, 2014, and 2015 Edition standards published by the Office of the National 

Coordinator for Health Information Technology (ONC). This has allowed IHS, Tribal and Urban Indian 

healthcare organization hospitals and providers to qualify for various Centers for Medicare and 

Medicaid Services (CMS) Meaningful Use incentives authorized by the Health Information
Technology for Economic and Clinical Health (HITECH) Act and to participate in CMS Quality 

Payment Programs. IHS has certified to the requirements that were due in 2022 for the ONC 2015 

Edition Cures Update per ONC’s timeline in the Federal Register. The IHS is continuing work to 

comply with the requirements due in 2023 as well. The IHS has utilized and incorporated numerous 

information technology standards promulgated by development organizations and specified in the 

various ONC Final Rules to meet the rigorous certification requirements.

The IHS Office of Information Technology maintains a website that references a number of the 

standards and policies in use by the agency that can be found at: 

(https://www.ihs.gov/oit/standardspolicy/) 

6) National Institutes of Health (NIH)

National Cancer Institute (NCI)

The Nanotechnology Characterization Laboratory (NCL) (https://ncl.cancer.gov/ ) is part of the 

Frederick National Laboratory for Cancer Research operated by Leidos Biomedical Research 

(contractor) for the National Cancer Institute (NCI). The NCL is guided by the NCI’s Alliance for 

Nanotechnology in Cancer, Cancer Imaging Program, the Division of Cancer Treatment and 

Diagnosis. The laboratory is dedicated to supporting the extramural research community.

The mission of the NCL is to advance the science of nanoparticle characterization. As part of these 

efforts, the NCL has developed 79 assays and 5 characterization guides for nanomaterial 

characterization, termed NCL’s Assay Cascade. All NCL assays are published on the NCL website and 

free to download: (https://www.cancer.gov/nano/research/ncl/protocols-capabilities).

Over 480 nanomaterial platform types have passed through the NCL Assay Cascade. The laboratory 

updates existing assays on a regular basis and develops and validates new assays to meet the needs 

of the nanotechnology research community. This year, one new protocol was added to our 

catalogue:

• PCC-22: Analysis of Residual Ethanol in Nanoformulations Using Headspace Gas 

Chromatography

• In addition to these assays, NCL commonly applies the following voluntary standards and guides:

• ISO Standard: TR 10993-22:2017: Biological evaluation of medical devices — Part 22: Guidance 

on nanomaterials

• ISO 10993-4:2017 Biological Evaluation of Medical Devices - Part 4: Selection Of Tests For 

Interactions With Blood

• USP <85> Bacterial Endotoxins Test, December 2012

NCL team members are also active participants of the standards organizations ASTM International 

and ISO, which develop voluntary consensus standards. NCL staff serve as subject matter experts in 

various nanotech-related working groups within these organizations. NCL has contributed to the 

development of ISO 29701:2010 “Nanotechnologies—Endotoxin test on nanomaterial samples for in 

vitro systems — Limulus amebocyte lysate (LAL) test”, and is currently working on a second ISO
standard, “Nanotechnologies—Total and free drug quantitation in doxorubicin hydrochloride 

liposomal formulations.”

NCL protocol ITA-8 was used as a foundation in the ASTM E3238-20 Standard Test Method For 

Quantitative Measurement Of The Chemoattractant Capacity Of A Nanoparticulate Material In Vitro. 

In 2022, the NCL has completed the revisions and renewal of three standard methods originally 

developed by the team in 2008:

• ASTM 2524-22: Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles

• ASTM 2525-22: Standard Test Method for Analysis of Nanoparticle Effects on CFU-GM

• ASTM 2526-22: Standard Test Method for Evaluation of Cytotoxicity of Nanoparticulate 

Materials in Porcine Kidney Cells and Human Hepatocarcinoma Cells.

This year, the FDA team finalized another ASTM standard, ASTM E3351-22 Standard Test Method for 

Detection of Nitric Oxide Production In Vitro, which is based on the NCL assay cascade protocol ITA7.

Efforts are also ongoing to bring 10 NCL protocols through ASTM as Standard Methods or Standard 

Guides. These efforts are continuing into 2023. The standards under development are:

• WK76862 Guide for the Identification of Nanoparticles Ability to Induce Infusion Reactions

• WK76861 Method for the In vivo analysis of nanoparticle-mediated physiological changes 

accompanying hypersensitivity reactions

• WK76860 Method for the Preparation and Analysis of Culture Supernatants for the Presence of 

Cytokine Biomarkers by Nanoparticles in Human Whole Blood Cultures

• WK76878 Method for the analysis of nanoparticle effects on human platelets in vitro

• WK76821 Practice for the Synthesis and Assembly of Nucleic Acid Nanoparticles

• WK76822 Method for the Preparation and Analysis of Culture Supernatants for the Presence of 

Cytokine Biomarkers by Nucleic Acid Nanoparticles in Human Peripheral Blood Mononuclear 

Cells

• WK76823 Guide for the Evaluation of Immunostimulatory Properties of Nucleic Acid 

Nanoparticles (NANPs)

National Library of Medicine (NLM)

The National Library of Medicine (NLM) has been a center of information innovation since its 

founding in 1836. The world’s largest biomedical library, NLM maintains and makes available a vast 

print collection and produces electronic information resources on a wide range of topics. NLM also 

supports and conducts research, development, and training in biomedical informatics and health 

information technology. In addition, the Library coordinates the 8,000-member Network of the 

National Library of Medicine that promotes and provides access to health information in 

communities across the United States.

NLM is active at a national level in the creation, review, and ongoing maintenance of standards 

related to the basic functions of a library including interlibrary loan, collection preservation, 

bibliographic control, and database creation and access. NLM’s goal is to ensure these standards
are workable for the library community as a whole. NLM participates in the National Information 

Standards Organization (NISO). Because NISO decisions feed into the decision-making process of the 

American National Standards Institute (ANSI), the official U.S. representative to the International 

Organization for Standardization (ISO), NLM’s activities extend to the development of standards at 

an international level. One example of an important NISO standard developed by NLM is the Journal 

Article Tag Suite,1 which is an outgrowth of NLM’s work on the PubMed Central journal article 

archive. Another example is NLM’s participation in the development of NISO’s new Recommended 

Practice: PIE-J: Presentation & Identification of E-Journals.

2

 Pie-J provides guidance to publishers of 

electronic journals on the presentation and identification of electronic journals to ensure long-term 

online accessibility to scholarly journals even after titles and publishers’ change.

For more than four decades, NLM has conducted and supported groundbreaking research and 

development related to the representation, interpretation, and use of biomedical knowledge in 

electronic forms including electronic health records (EHRs). NLM has been the central coordinating 

body for clinical terminology standards within the Department of Health and Human Services (HHS) 

since 2004. In this role, NLM is the official depository and distribution center for clinical 

terminologies, responsible for integrating them within the Unified Medical Language System (UMLS) 

Metathesaurus and for developing and maintaining mappings between designated standard clinical 

terminologies and important related terminologies, including the HIPAA code sets. NLM works with 

(and, in some cases, provides funding to) vocabulary developers, message standards development 

organizations, other Federal agencies, and users of standards to fulfill its role as the central 

coordinating body for clinical terminology standards and to respond to recommendations from the 

Health Information Technology Advisory Committee. Clinical terminology standards and resources 

supported or produced by NLM includes:

• UMLS Metathesaurus – Produced by NLM, this resource incorporates many different 

vocabularies, classifications, and code sets. While not a standard in and of itself, it is an 

important resource to help the research and healthcare community understand the breadth of 

available standards and how they relate to one another

• LOINC (Logical Observations Identifiers Names and Codes) – NLM funds the ongoing 

maintenance and free distribution of this standard with codes names and other information for 

reporting and ordering laboratory tests, measurements, survey instrument and other kinds of 

observations (accessible within the UMLS Metathesaurus and from the Regenstrief Institute). 

LOINC can be accessed worldwide via a web tool (SearchLOINC) which enables searches for tests 

and measures, their descriptions, units of measure, synonyms, and tests/measures. LOINC can 

also be downloaded as a whole or as its component parts including the LOINC tables, Hierarchy, 

Document Ontology, linguistic variations, mappings between RadLex (Radiology codes) and 

LOINC codes, and mappings between IEEE instrument codes and LOINC codes. LOINC works 

closely with HL7 FHIR. It includes a standard FHIR vocabulary server and the LOINC content is all

1 http://www.niso.org/apps/group_public/project/details.php?project_id=93

2

https://www.nlm.nih.gov/bsd/policy/piej_niso_practices.html
provided on FHIR’s own vocabulary server. LOINC supports sets of variables, including 

laboratory panels such as CBC, and survey instruments. LOINC panels provide information 

needed to generate a FHIR questionnaire (data collection form) and can support all the special 

features of FHIR questionnaires, i.e., skip logic, pre-population from FHIR medical records, etc. 

FHIR questionnaires can be generated on the fly as web data input forms

• SNOMED CT – NLM is the US representative to SNOMED International and as such pays the 

annual fee that permits U.S.-wide use of SNOMED CT (comprehensive clinical healthcare 

terminology; accessible within the UMLS Metathesaurus and in native format from NLM) and 

creation and distribution of the U.S. Edition of SNOMED CT

• RxNorm – NLM produces and distributes RxNorm (terminology for clinical drugs; accessible both 

within the UMLS Metathesaurus and separately from NLM). RxNorm provides normalized names 

for clinical drugs and links to many drug vocabularies commonly used in pharmacy management 

and drug interaction software. By providing links between these vocabularies, RxNorm can 

mediate messages between systems not using the same software and vocabulary. NLM provides 

several web-based programs for retrieving data from several drug sources including RxNorm

API, RxTerms API, RxClass API, and Drug Interaction API. Another resource, RxNav, is a browser 

for several drug information sources, including RxNorm, RxTerms and MED-RT. These programs 

are quite popular. For example, the RxNav API receives more than 1.6 billion API queries 

annually.

• UCUM (Unified Code for Units of Measure) – Developed by the Regenstrief Institute with 

funding from NLM UCUM is a code system intended to include all units of measures being 

contemporarily used in international science, engineering, and business. The purpose is to 

facilitate unambiguous electronic communication of quantities together with their units.

• LOINC, SNOMED CT, RxNorm and UCUM form a suite of key clinical terminology standards that 

have been designated for use in the U.S. healthcare systems over the past 20 years:

o Consolidated Health Informatics (CHI; active 2001 - 2007) - eGov project designated the 

suite as U.S. Government-wide clinical standards for use in U.S. Federal Government 

healthcare systems.

o Healthcare Information Technology Standards Panel (HITSP; active 2005 - 2010) -

identified the suite in various interoperability specifications for use throughout the U.S. 

healthcare spectrum. The suite was required for use in U.S. Federal Government 

healthcare systems, recommended for use in the private sector.

o Health Information Technology for Economic and Clinical Health (HITECH) Act - In July 

2010 the suite were named as standards to support stage 1 meaningful use in the 

“Health Information Technology Standards, Implementation Specifications, and 

Certification Criteria and Certification Programs for Health Information Technology” 

Final Rule. Subsequent final rules for EHR certification criteria (2011, 2014, and 2015
Editions) each expanded the requirements for use of the suite to support meaningful 

use.

• United States Core Data for Interoperability (USCDI) – Established by the Office of the National 

Coordinator for Health Information Technology (ONC) as part of the Cures Act Final Rule, USCDI 

is a standardized set of health data classes and constituent data elements for nationwide, 

interoperable health information exchange. A USCDI data element is the most granular level at 

which a piece of data is exchanged. The USCDI specifies the set of coding systems that are 

required for use in US electronic medical record systems to support interoperable health 

information exchange. In this system, SNOMED CT, LOINC, and RxNorm and UCUM are all 

required for use for designated purposes.

• Interoperability Standards Advisory (ISA) – Established by the Office of the National 

Coordinator for Health Information Technology (ONC), ISA is the model by which ONC 

coordinates the identification, assessment, and public awareness of interoperability standards 

and implementation specifications for use in healthcare systems. ISA specifies LOINC, SNOMED 

CT, and RxNorm and UCUM as the preferred coding system for designed purposes.

• Health Level Seven (HL7) Standards for Genetics – LOINC has been selected as the core 

structure of three HL7 standards genetics including 1) HL7 V2 specification for cytogenetics, 2) 

laboratory reporting of genetic variants, and 3) HL7 FHIR specification for clinical genetic 

reports.

• LOINC In Vitro Diagnostic (LIVD) Test Code Mapping for SARS-CoV-2 Tests – Announced by HHS 

on June 4, 2020, LIVD is new laboratory data reporting guidance for COVID-19 testing. LIVD uses 

LOINC and SNOMED CT to identify and report SARS-CoV-2 test results in electronic reporting 

systems to facilitate timely and quality data reporting to state and federal public health agencies 

(https://www.cdc.gov/csels/dls/sars-cov-2-livd-codes.html). It was an essential ingredient in the 

quick (few days) generation of COVID-19 test codes produced by the collaboration between

CDC, FDA, Regenstrief (LOINC), SNOMED International, APHL and the IVD industry connectivity 

consortium.

• Health Level Seven (HL7) Fast Healthcare Interoperability Resources (FHIR) – NLM has been an 

active proponent of the FHIR standard that is now supported at the National Institutes of Health 

(NIH) level to support data science, see (https://datascience.nih.gov/fhir-initiatives). Both the 

Office of the National Coordinator for Health Information Technology (ONC) and the Centers for 

Medicare and Medicaid Services (CMS) include requirements for use of FHIR in recent 

rulemaking related to the 21st Century Cures Act. NLM’s specific focus is on exploring the 

creation of FHIR-compliant API for clinical research use, starting by standardizing phenotype 

data for several large population cohort studies archived within the database of Genotypes and 

Phenotypes (DbGap). NLM has also developed several software tools to facilitate use of FHIR 

(https://lhcforms.nlm.nih.gov). Users and developers downloaded some of these tools nearly
100,000 times in 2021. NLM’s National Center for Biotechnology Information (NCBI) maintains 

databases of genetic variants (ClinVar, dbSNP) that are required coding systems for HL7 FHIR 

genetic reporting (http://ncbi.nlm.nih.gov). In addition, SNOMED CT is the standard for selected 

data elements in international genetic information resources, including the NIH Genetic Testing 

Registry and the ClinVar database of clinically significant human variations. It is also being used 

in an increasing number of clinical research studies.

NLM, on behalf of HHS, is the U.S. Member of the International Health Terminology Standards 

Development Organisation (IHTSDO; using the trading name SNOMED International) which owns, 

maintains, and distributes SNOMED CT internationally and promotes global standardization of 

health information. As the US Member, NLM produces and distributes:

• US Edition to SNOMED CT – combination of the U.S. Extension and the International Release of 

SNOMED CT. The U.S. Edition to SNOMED CT is the version of SNOMED CT cited as CMS 

Promoting Interoperability program requirements. The US Extension is a formal extension of 

the International Release that allows NLM to provide both rapid access to SNOMED CT concepts 

needed by U.S. stakeholders, as well as standard terminology needed for U.S. clinical use cases 

(e.g. regulatory or legislatively mandated terms specific to the U.S.) that are not generally useful 

in other countries.

• CORE Problem List Subset of SNOMED CT – updated 4 times per year (with each new release of 

SNOMED CT and the UMLS Metathesaurus). The Subset is designed to facilitate the use of 

SNOMED CT for coding of problem list data in EHRs and to enable more meaningful use of EHRs 

to improve patient safety, health care quality, and health information exchange. Development 

and distribution of this initial subset was used as a model for development of other frequencybased subsets to facilitate implementation of SNOMED CT, LOINC, and RxNorm throughout the

U.S. including:

o SNOMED CT Route of Administration

o Nursing Problem List Subset of SNOMED CT

o Universal Laboratory Order Codes from LOINC and Common UCUM Codes (both created 

in conjunction with the Regenstrief Institute)

o RxNorm Current Prescribable Content

• Mappings - between standard clinical vocabularies, HIPAA code sets, and other key vocabularies 

used in Federal health information systems. The mappings are intended to facilitate 

development and implementation by health care providers of EHRs that capture clinical data at 

the point of care and subsequently support generation of required HIPAA code set data for 

claims and other administrative transactions. Mappings maintained and distributed by NLM:

o SNOMED CT to ICD-10 – updated and expanded in conjunction with the IHTSDO

o SNOMED CT to ICD-10-CM – builds on and makes use of the tools and policies 

developed for the IHTSDO mapping project.
o ICD-9-CM to SNOMED CT – Designed to further facilitate the transition from ICD-9-CM

to SNOMED CT, NLM makes available maps from heavily used ICD-9-CM procedure

codes to SNOMED CT as well as the map from heavily used ICD-9-CM diagnostic codes to 

SNOMED CT. Both maps are based on in-patient claims data obtained from CMS.

o Nursing Resources for Standards and Interoperability - a resource for anyone 

interested in nursing terminologies for systems development. The page describes the 

role of SNOMED CT and LOINC in implementing meaningful use, specifically for the 

nursing and care domain.

As the U.S. Member of the IHTSDO, NLM also:

• Makes available the U.S. SNOMED CT Content Request System (USCRS) in support of the U.S. 

Extension to SNOMED CT. USCRS is a mechanism for U.S. stakeholders to request changes to 

SNOMED CT (e.g. new concepts or enhancements to existing concepts). The long-term goal is 

to allow the establishment of a network for U.S. contributions to the development of SNOMED 

CT by both government agencies and private sector organizations and enable collaboration with 

other IHTSDO member countries in the development of SNOMED CT content and subsets.

• Facilitates alignment and harmonization - NLM continues working with the IHTSDO to facilitate 

alignment and harmonization between SNOMED CT and other key health terminologies, most 

notably with LOINC.

NLM provides access to several additional resources to make standards more accessible:

• MedlinePlus Connect - a free service that delivers consumer-oriented information about 

relevant conditions and disorders, health and wellness, and prescription and over-the-counter 

medications to patients, families, and health care providers via EHR systems. The system works 

by accepting specific requests from EHR systems and providing in response links to relevant 

consumer health information from NLM’s MedlinePlus system. To facilitate the connection, 

NLM mapped all MedlinePlus health topics pages to standard coding systems used in EHRs. 

Specifically, MedlinePlus Connect responds to requests for information based on diagnosis 

(problem) codes (SNOMED CT CORE Problem List Subset, ICD-9-CM, ICD-10-CM), medication 

codes (RxNorm, NDC), and lab test codes (LOINC). Code requests will then receive relevant 

health information from MedlinePlus, Genetics Home Reference, and other reliable health 

resources.

• Value Set Authority Center (VSAC) - NLM, in collaboration with the Office of the National 

Coordinator for Health Information Technology (ONC) and Centers for Medicare & Medicaid 

Services (CMS) created VSAC, which was launched in early FY2013. The system has since been 

expanded to include an authoring tool that allows users to author value sets in a collaborative 

environment. NLM continues working with ONC and CMS to enhance and expand VSAC to meet 

the community’s needs.
• AccessGUDID (Global Unique Device Identification Database) – NLM, in conjunction with the 

Food and Drug Administration (FDA), introduced AccessGUDID in FY2015. This web resource 

contains key device identification information submitted to the FDA about medical devices that 

have Unique Device Identifiers (UDI).

• Newborn Screening laboratory reporting – NLM, in collaboration with CDC, FDA, Health 

Resources and Services Administration (HRSA), and other NIH institutes and centers, as well as 

with the American Public Health Laboratory (APHL) and many state public health departments 

develop and maintain an HL7 v.2.5.1 laboratory reporting guide for newborn screening result 

reporting. The guide leverages LOINC, SNOMED CT, and HL7 messaging structures to support the 

timely communication of newborn screening results and conditions.

• NIH Common Data Elements (CDE) Repository - developed and maintained by NLM on behalf of 

NIH, the CDE repository provides access to structured human and machine-readable definitions 

of data elements that have been recommended or required by NIH for use in research and other 

purposes. The repository helps facilitate standardization by providing tooling (search, browse, 

compare) that can be used in the harmonization and de-duplication of data elements.

NLM works closely with the HHS Office of the National Coordinator for Health Information 

Technology (ONC) to ensure NLM’s vocabulary harmonization and standards efforts are in sync with 

those of ONC and the Health Information Technology Advisory Committee (HITAC). NLM participates 

in the HITAC and has participated in its predecessors, the Health IT Policy Committee and the Health 

IT Standards Committee as a member. HITAC assumes responsibility for evaluating vocabularies and 

information models needed to achieve greater interoperability across healthcare systems, to 

“Promote Interoperability”, and other federal requirements. NLM also participates in the Federal 

Health IT Coordinating Council.

NLM participates in the International Organization for Standards (ISO) Health Informatics Technical 

Committee (ISO/TC 215) to provide advice at the national (ANSI) and international (ISO) levels. This 

groups scope is “standardization in the field of health informatics, to facilitate capture, interchange 

and use of health-related data, information, and knowledge to support and enable all aspects of the 

health system.

A complete list of NLM’s activities relating to health information technology and health data 

standards is available from the NLM Website at (http://www.nlm.nih.gov/healthit.html).
7) Office of the National Coordinator (ONC)

Standards are an integral component of ONC’s mission to support the development of a nationwide 

health information technology (health IT) infrastructure that allows for electronic use and exchange 

of information in a scalable manner, promotes the adoption of interoperable health IT in a costeffective manner, and provides leadership in the development, recognition, and implementation of 

standards and certification of health IT products. The consistent use of health IT standards is a 

necessary requirement to achieve interoperability of health information, which is a central key to 

reducing health care costs.

One way in which ONC encourages the consistent use of health IT standards is through ONC's Health 

IT Certification Program which is composed of functional requirements known as “certification 

criteria.” Health IT standards are part of the certification criteria. Developers certify their Health IT 

Modules by demonstrating conformance to these certification criteria, using test procedures (that 

may have associated test tools and/or test data) approved by the National Coordinator. Additionally, 

ONC provides clarifications to certification criteria through Certification Companion Guides (CCG)

designed to assist with health IT product development.

One of the standards used in certification criteria is the United States Core Data for Interoperability 

(USCDI) which is a standardized set of health data classes and constituent data elements for 

nationwide, interoperable health information exchange. It establishes a baseline set of data that can 

be commonly exchanged across care settings for a wide range of uses. In 2020, ONC published 

USCDI Version 1 and created an annual process for updating the USCDI based on public input. In 

2022, ONC published USCDI Version 3 after going through the annual process and is now working on 

developing USCDI Version 4.

Additionally, ONC continues to use the Health Information Technology Advisory Committee (HITAC) 

to review proposed drafts of the USCDI as one means to get expert feedback before finalizing each 

version. The USCDI’s impact is not limited to health IT products certified under the ONC Health IT 

Certification Program. The ONC Cures Act Final Rule provisions related to “information blocking” 

also reference the USCDI as the initial scope of electronic health information (EHI) healthcare 

providers, health information networks and exchanges, and developers of certified health IT need to 

consider when it comes to the access, exchange, and use of EHI. Please see the USCDI v2 and the 

USCDI Fact Sheet for more information.

The Standards Version Advancement Process (SVAP) enables health IT developers to voluntarily 

incorporate newer versions of specific ONC-regulated standards and implementation specifications 

into their products under the ONC Health IT Certification Program, including future versions of the 

USCDI. The SVAP advances interoperability by permitting developers of certified health IT to 

implement newer versions of standards and specifications than currently adopted in regulation. In 

2020, ONC established an annual public comment process for SVAP-eligible standards and
implementation specifications. In 2022, ONC announced the “Approved Standards for 2022.” 

Please see the SVAP Approved Standards on the ONC Certification Program SVAP webpage.

ONC provides some funding and works with the standards development organization named the 

Regenstrief Institute, in their development of Logical Observations Identifiers, Names and Codes 

(LOINC), a health IT standard for reporting and ordering laboratory tests, measurements, and other 

observations.

Another standard development organization that ONC works closely with and provides funding to is 

Health Level Seven (HL7) to support the development and ongoing maintenance of Fast Healthcare 

Interoperability Resources (FHIR) standard and related implementation guides along with their 

Consolidated Clinical Document Architecture (CCDA) standard. These standards are referenced in 

ONC’s certification program and enables nationwide interoperability.

Additionally, ONC works with Integrating the Healthcare Enterprise (IHE) a non-profit organization 

that creates guidance, called “profiles”, by combining a variety of standards and documents how 

they work together in order to support a specific use case. ONC’s focus with IHE has largely been 

related to updating IHE profiles to use the HL7 FHIR standard.

Related Links

https://www.healthit.gov/topic/standards-technology/onc-standards-bulletin

https://www.healthit.gov/isa/united-states-core-data-interoperability-uscdi

https://www.healthit.gov/isa/standards-version-advancement-process

https://www.healthit.gov/topic/standards-version-advancement-process-svap

https://www.healthit.gov/topic/certification-ehrs/certification-health-it

8) Substance Abuse and Mental Health Services Administration (SAMHSA)

The Substance Abuse and Mental Health Services Administration (SAMHSA) is a member of the 

National Quality Forum (NQF), a voluntary consensus body for performance measurement. SAMHSA 

works with NQF, as well as public and private-sector partners, as part of NQF’s Measure Application 

Partnership to recommend quality measures to the Department of Health and Human Services 

(HHS) for federal reporting.

Additionally, SAMHSA works with NQF, as well as private and public stakeholders, as part of the 

Medicaid and Children’s Health Insurance Program Scorecard Workgroup that provides input to HHS 

on quality measures that will be included in the Centers for Medicare and Medicaid Services (CMS) 

public reporting efforts.

As a member of the NQF, SAMHSA collaborates with a number of federal partners, including, the 

office of the Assistant Secretary for Planning and Evaluation, and CMS, to develop behavioral health
quality measures that address key gaps in the field related to substance use and mental health 

disorders. Some of these measures have been used in different stages of “Meaningful Use” and are 

now part of the Medicaid Adult and Child Core Sets of Measures and the Merit-based Incentive 

Payment System (MIPS).

These Adult Healthcare Quality measures can be found at: 

(https://www.medicaid.gov/medicaid/quality-of-care/performance-measurement/adult-and-childhealth-care-quality-measures/adult-health-care-quality-measures/index.html)

2023 and 2024 Core Set of Adult Health Care Quality Measures for Medicaid (Adult Core Set): 

(https://www.medicaid.gov/sites/default/files/2022-11/2023-adult-core-Set.pdf) 

2023 and 2024 Core Set of Children’s Health Care Quality Measures for Medicaid and CHIP (Child 

Core Set): (https://www.medicaid.gov/sites/default/files/2022-11/2023-child-core-set.pdf) 

The 2023 MIPS Quality Measures can be found at: (https://qpp-cm-prodcontent.s3.amazonaws.com/uploads/2217/2023%20MIPS%20Quality%20Measures%20List.xlsx) 

2. Please list the government-unique standards (GUS) your agency began using in lieu of voluntary 

consensus standards during FY 2022. Please note that GUS which are still in effect from previous 

years should continue to be listed, thus the total number in your agency's report will include all 

GUS currently in use (previous years and new as of this FY):

Current total GUS = 1 

Table 1: Current Government Unique Standards FY2023

(1) Government Unique Standard

FDA Guidelines on Asceptic Processing (2004) [Incorporated: 2004]

Voluntary Standard

ISO 13408-1 Asceptic Processing of Health Care Products, Part 1, General Requirements

Rationale

FDA is not using the ISO standard because the applicability of these requirements is limited to only 

portions of aseptically manufactured biologics and does not include filtration, freeze-drying, sterilization in 

place, cleaning in place, or barrier-isolator technology. There are also significant issues related to 

aseptically produced bulk drug substance that are not included in the document